SCHEMBL3769583

SCHEMBL3769583

CCOC(=O)c1cn2cc(C#C[Si](C)(C)C)ccc2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 8/20 0.56
▸ POLB P06746 1/20 0.56
▸ GABRA2 P47869 4/20 0.48
▸ GABRA1 P14867 3/20 0.48
▸ GABRA5 P31644 3/20 0.48
▸ GABRG2 P18507 2/20 0.48
▸ GABRB3 P28472 2/20 0.48
▸ GABRA3 P34903 2/20 0.48
▸ GABRA4 P48169 2/20 0.48
▸ GABRA6 Q16445 2/20 0.48
▸ GAA P10253 1/20 0.48
▸ RAB9A P51151 5/20 0.46
▸ NPC1 O15118 3/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ CYP1A2 P05177 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1638034 0.83 KDM4E (0.61) KDM4EPOLBGABRA2GAARAB9A
SCHEMBL3762711 0.83 KDM4E (0.60) KDM4EPOLBGABRA2GAARAB9A
SCHEMBL1733645 0.83 PTGS1 (0.48) KDM4EPOLBGABRA2GABRA1GABRA5
SCHEMBL871014 0.80 KDM4E (0.69) KDM4EPOLBGABRA2GAARAB9A
SCHEMBL118658 0.77 KDM4E (0.66) KDM4EPOLBGABRA2GAARAB9A
SCHEMBL24066036 0.77 KDM4E (0.60) KDM4EPOLBGABRA2GAARAB9A
SCHEMBL70705 0.76 KDM4E (0.64) KDM4EPOLBGABRA2GAARAB9A
SCHEMBL3545619 0.76 KDM4E (0.64) KDM4EPOLBGABRA2GAARAB9A
SCHEMBL4098270 0.76 KDM4E (0.64) KDM4EPOLBGABRA2GAARAB9A
SCHEMBL1500236 0.76 KDM4E (0.64) KDM4EPOLBGABRA2GAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111542523-B Heterocyclic compounds as PRMT5 inhibitors 朱比连特埃皮斯科瑞有限责任公司 2024-03-29 — — CN disclosed
US-20210371431-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT EPISCRIBE LLC 2021-12-02 — — US disclosed
US-8691990-B2 6-heterocyclic imidazo[1,2-α]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof SANOFI (FR) 2014-04-08 — — US disclosed
US-20130041152-A1 6-HETEROCYCLIC IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF PEYRONEL JEAN-FRANCOIS (FR) 2013-02-14 — — US disclosed
US-8314109-B2 6-heterocyclic-imidazo[1,2-α]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof SANOFI (FR) 2012-11-20 — — US disclosed
US-20100317686-A1 N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 — — US disclosed
US-20100317675-A1 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130041152-A1 6-HETEROCYCLIC IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF XDH, REN, IDH2 KDM4E 2724/4885POLB 3310/4885GABRA2 53/4885
US-20100317675-A1 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF REN, IDH2, GLS KDM4E 2460/4885POLB 3774/4885GABRA2 79/4885
US-20210371431-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 KDM4E 221/4885POLB 1269/4885GABRA2 4122/4885
US-20100317686-A1 N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF IDH1, IDH2, XDH KDM4E 2759/4885POLB 3859/4885GABRA2 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback